SGLT2抑制剂在老年或衰弱2型糖尿病合并心衰患者中的系统综述与荟萃分析
该系统综述与荟萃分析纳入20项研究(22篇报告,N=77,083),评估SGLT2抑制剂在老年(>65岁)或衰弱2型糖尿病合并心衰患者中的疗效与安全性。结果显示SGLT2抑制剂未显著降低HbA1c,但显著降低全因死亡、心源性死亡及心衰住院风险,未显著增加糖尿病酮症酸中毒或急性肾损伤风险。
要点
- SGLT2抑制剂未显著降低老年或衰弱T2D合并HF患者的HbA1c水平。
- SGLT2抑制剂显著降低全因死亡、心源性死亡和心衰住院风险。
- SGLT2抑制剂未显著增加糖尿病酮症酸中毒或急性肾损伤风险。
核心结论
- 在老年或衰弱2型糖尿病合并心衰患者中,SGLT2抑制剂与全因死亡和心血管事件总体负担(包括心衰住院和心源性死亡)降低相关,但对大血管死亡或肾脏事件无保护作用。
研究设计与样本
- 系统综述与荟萃分析,检索PubMed、Scopus、Web of Science、Cochrane CENTRA和Google Scholar,纳入比较SGLT2抑制剂与安慰剂/其他降糖药的随机对照试验和观察性研究,对象为衰弱或年龄>65岁的2型糖尿病合并心衰患者,共纳入20项研究(22篇报告,N=77,083)。
主要发现
- SGLT2抑制剂未显著降低HbA1c水平(平均差-0.13,95%CI:-0.41至0.14)。
- SGLT2抑制剂显著降低全因死亡风险(RR 0.81,95%CI:-0.69至0.95)。
- SGLT2抑制剂显著降低心源性死亡风险(RR 0.80,95%CI:-0.94至0.69)。
- SGLT2抑制剂显著降低心衰住院风险(RR 0.69,95%CI:0.59-0.81)。
- SGLT2抑制剂未显著降低大血管事件、肾脏进展/复合肾脏终点、急性肾损伤、心衰恶化、心房颤动或糖尿病酮症酸中毒风险。
临床怎么用
- 在老年或衰弱2型糖尿病合并心衰患者中,可考虑使用SGLT2抑制剂以降低全因死亡、心源性死亡和心衰住院风险。
- 使用SGLT2抑制剂时需注意其未显著增加糖尿病酮症酸中毒或急性肾损伤风险,但仍应个体化评估。
局限性
- 不良事件难以量化,但糖尿病酮症酸中毒或急性肾损伤风险未显著增加。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Sodium-glucose cotransporter-2 inhibitors (SGLT2Is) reduce cardio-metabolic and renal outcomes in patients with type 2 diabetes (T2D) but their efficacy and safety in older or frail individuals remains unclear. METHODS: We searched PubMed, Scopus, Web of Science, Cochrane CENTRA and Google Scholar and selected randomised controlled trials and observational studies comparing SGLT2Is versus placebo/other glucose-lowering agent for people with frailty or older individuals (>65 years) with T2D and heart failure (HF). Extracted data on the change in HbA1c % and safety outcomes were pooled in a random-effects meta-analysis model. RESULTS: We included data from 20 studies (22 reports; N = 77,083 patients). SGLT2Is did not significantly reduce HbA1c level (mean difference -0.13, 95%CI: -0.41 to 0.14). SGLT2Is were associated with a significant reduction in the risk of all-cause mortality (risk ratio (RR) 0.81, 95%CI: -0.69 to 0.95), cardiac death (RR 0.80, 95%CI: -0.94 to 0.69) and hospitalisation for heart failure (HHF) (RR 0.69, 95%CI: 0.59-0.81). However, SGLT2Is did not demonstrate significant effect in reducing in the risk of macrovascular events (acute coronary syndrome or cerebral vascular occlusion), renal progression/composite renal endpoint, acute kidney injury, worsening HF, atrial fibrillation or diabetic ketoacidosis. CONCLUSIONS: In older or frail patients with T2D and HF, SGLT2Is are consistently linked with a decrease in total mortality and the overall burden of cardiovascular (CV) events, including HHF events and cardiac death, but not protective for macrovascular death or renal events. Adverse events were more difficult to quantify but the risk of diabetic ketoacidosis or acute kidney injury was not significantly increase.
引用
- Aldafas R, Crabtree T, Alkharaiji M, et al. Sodium-glucose cotransporter-2 inhibitors (SGLT2) in frail or older people with type 2 diabetes and heart failure: a systematic review and meta-analysis. Age Ageing. 2024. PMID: 38287703. doi:10.1093/ageing/afad254
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。